Reuters logo
BRIEF-NOXXON Pharma signs clinical immuno-oncology collaboration agreement with MSD to study NOX-A12 combined with Keytruda (Pembrolizumab) in pancreatic and colorectal cancer
2016年12月15日 / 上午11点05分 / 9 个月前

BRIEF-NOXXON Pharma signs clinical immuno-oncology collaboration agreement with MSD to study NOX-A12 combined with Keytruda (Pembrolizumab) in pancreatic and colorectal cancer

Dec 15 (Reuters) - Noxxon Pharma AG :

* Two companies will collaborate in a Phase 1/2 clinical trial of NOXXON’s ANTI-CXCL12 agent, NOX-A12, and MSD’s anti-PD-1 inhibitor, Keytruda (Pembrolizumab)

* Total of twenty patients will be recruited, ten of each cancer type

* Noxxon will be sponsor of study, which will be conducted in Europe Source text for Eikon: Further company coverage: (Gdynia Newsroom)

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below